Creative Medical Technology Holdings, Inc. (CELZ) Free cash flow
- Free cash flow · 12 months (USD): Value (m); Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | (m) | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-5.90M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.98× | Operating cash flow / net income. Period ending 2026-06-30. $-5.90M ÷ $-6.04M ≈ 0.98× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -5.90M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations |
| Capital spending | (m) | |
| Market cap | (m) | |
| Free cash flow | (m) | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations |
| Revenue | 3.00K USD | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -6.04M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $-5.90M | (m) | (m) | $3.00K | (m) | $-6.04M | (m) | (m) | (m) | 0.98× |
| 2026-03-31 | (m) | (m) | $-5.59M | (m) | (m) | $3.00K | (m) | $-5.76M | (m) | (m) | (m) | 0.97× |
| 2025-12-31 | (m) | (m) | $-5.86M | (m) | (m) | $6.00K | (m) | $-6.00M | (m) | (m) | (m) | 0.98× |
| 2025-09-30 | (m) | (m) | $-5.87M | (m) | (m) | $6.00K | (m) | $-5.96M | (m) | (m) | (m) | 0.98× |
| 2025-06-30 | (m) | (m) | $-5.69M | (m) | (m) | $6.00K | (m) | $-5.77M | (m) | (m) | (m) | 0.99× |
| 2025-03-31 | (m) | (m) | $-6.00M | (m) | (m) | $14.00K | (m) | $-6.09M | (m) | (m) | (m) | 0.98× |
| 2024-12-31 | (m) | (m) | $-5.30M | (m) | (m) | $11.00K | (m) | $-5.49M | (m) | (m) | (m) | 0.97× |
| 2024-09-30 | (m) | (m) | $-5.25M | (m) | (m) | $11.00K | (m) | $-5.32M | (m) | (m) | (m) | 0.99× |
| 2024-06-30 | (m) | (m) | $-5.57M | (m) | (m) | $17.00K | (m) | $-5.73M | (m) | (m) | (m) | 0.97× |
| 2024-03-31 | (m) | (m) | $-5.08M | (m) | (m) | $9.00K | (m) | $-5.28M | (m) | (m) | (m) | 0.96× |
| 2023-12-31 | (m) | (m) | $-8.03M | (m) | (m) | $9.00K | (m) | $-5.29M | (m) | (m) | (m) | 1.52× |
| 2023-09-30 | (m) | (m) | $-9.72M | (m) | (m) | $24.60K | (m) | $-9.82M | (m) | (m) | (m) | 0.99× |
| 2023-06-30 | (m) | (m) | $-9.29M | (m) | (m) | $73.60K | (m) | $-9.35M | (m) | (m) | (m) | 0.99× |
| 2023-03-31 | (m) | (m) | $-10.06M | (m) | (m) | $73.60K | (m) | $-10.04M | (m) | (m) | (m) | 1.00× |
| 2022-12-31 | (m) | (m) | $-7.80M | (m) | (m) | $88.60K | (m) | $-10.14M | (m) | (m) | (m) | 0.77× |
| 2022-09-30 | (m) | (m) | $-5.37M | (m) | (m) | $137.75K | (m) | $-7.80M | (m) | (m) | (m) | 0.69× |
| 2022-06-30 | (m) | (m) | $-4.88M | (m) | (m) | $92.75K | (m) | $-8.67M | (m) | (m) | (m) | 0.56× |
| 2022-03-31 | (m) | (m) | $-3.35M | (m) | (m) | $102.75K | (m) | $-9.78M | (m) | (m) | (m) | 0.34× |
| 2021-12-31 | (m) | (m) | $-2.22M | (m) | (m) | $87.75K | (m) | $19.21M | (m) | (m) | (m) | -0.12× |
| 2021-09-30 | (m) | (m) | $-997.46K | (m) | (m) | $37.50K | (m) | $-15.53M | (m) | (m) | (m) | 0.06× |
| 2021-06-30 | (m) | (m) | $-780.68K | (m) | (m) | $104.50K | (m) | $-13.29M | (m) | (m) | (m) | 0.06× |
| 2021-03-31 | (m) | (m) | $-680.75K | (m) | (m) | $122.40K | (m) | $-12.23M | (m) | (m) | (m) | 0.06× |
| 2020-12-31 | (m) | (m) | $-434.56K | (m) | (m) | $164.50K | (m) | $-36.33M | (m) | (m) | (m) | 0.01× |
| 2020-09-30 | (m) | (m) | $-743.97K | (m) | (m) | $142.60K | (m) | $-2.90M | (m) | (m) | (m) | 0.26× |
| 2020-06-30 | (m) | (m) | $-928.24K | (m) | (m) | $123.10K | (m) | $-5.70M | (m) | (m) | (m) | 0.16× |
| 2020-03-31 | (m) | (m) | $-1.14M | (m) | (m) | $156.80K | (m) | $-3.94M | (m) | (m) | (m) | 0.29× |
| 2019-12-31 | (m) | (m) | $-1.21M | (m) | (m) | $165.50K | (m) | $-8.48M | (m) | (m) | (m) | 0.14× |
| 2019-09-30 | (m) | (m) | $-1.26M | (m) | (m) | $227.50K | (m) | $-1.36M | (m) | (m) | (m) | 0.93× |
| 2019-06-30 | (m) | (m) | $-1.24M | (m) | (m) | $222.40K | (m) | $-522.27K | (m) | (m) | (m) | 2.38× |
| 2019-03-31 | (m) | (m) | $-1.16M | (m) | (m) | $165.60K | (m) | $-6.87M | (m) | (m) | (m) | 0.17× |
| 2018-12-31 | (m) | (m) | $-1.05M | (m) | (m) | $124.40K | (m) | $-13.66M | (m) | (m) | (m) | 0.08× |
| 2018-09-30 | (m) | (m) | $-879.36K | (m) | (m) | $71.60K | (m) | $-17.07M | (m) | (m) | (m) | 0.05× |
| 2018-06-30 | (m) | (m) | $-806.10K | (m) | (m) | $19.20K | (m) | $-15.55M | (m) | (m) | (m) | 0.05× |
| 2018-03-31 | (m) | (m) | $-830.81K | (m) | (m) | $14.40K | (m) | $-10.00M | (m) | (m) | (m) | 0.08× |
| 2017-12-31 | (m) | (m) | $-889.62K | (m) | (m) | $4.80K | (m) | $-2.66M | (m) | (m) | (m) | 0.33× |
| 2017-09-30 | (m) | (m) | $-61.84K | (m) | (m) | $0.00 | (m) | $-1.38M | (m) | (m) | (m) | 0.04× |
| 2017-06-30 | (m) | (m) | $-799.50K | (m) | (m) | $0.00 | (m) | $-1.54M | (m) | (m) | (m) | 0.52× |
| 2017-03-31 | (m) | (m) | $-668.98K | (m) | (m) | $0.00 | (m) | $-861.58K | (m) | (m) | (m) | 0.78× |
| 2016-12-31 | (m) | (m) | $445.23K | (m) | (m) | $0.00 | (m) | $-766.07K | (m) | (m) | (m) | -0.58× |
| 2016-09-30 | (m) | (m) | $-261.75K | (m) | (m) | $0.00 | (m) | $-580.53K | (m) | (m) | (m) | 0.45× |
| 2016-03-31 | (m) | (m) | $-9.27K | (m) | (m) | $0.00 | (m) | $-26.63K | (m) | (m) | (m) | 0.35× |
| 2015-12-31 | (m) | (m) | $-14.64K | (m) | (m) | $0.00 | (m) | $-30.76K | (m) | (m) | (m) | 0.48× |
| 2015-09-30 | (m) | (m) | $-18.05K | (m) | (m) | $0.00 | (m) | $-28.34K | (m) | (m) | (m) | 0.64× |
| 2015-06-30 | (m) | (m) | $-18.30K | (m) | (m) | $0.00 | (m) | $-27.80K | (m) | (m) | (m) | 0.66× |
| 2015-03-31 | (m) | (m) | $-18.61K | (m) | (m) | $0.00 | (m) | $-27.27K | (m) | (m) | (m) | 0.68× |
| 2014-12-31 | (m) | (m) | $-17.32K | (m) | (m) | $0.00 | (m) | $-28.01K | (m) | (m) | (m) | 0.62× |
| 2014-09-30 | (m) | (m) | $-16.28K | (m) | (m) | $0.00 | (m) | $-27.56K | (m) | (m) | (m) | 0.59× |
| 2014-06-30 | (m) | (m) | $-17.31K | (m) | (m) | $0.00 | (m) | $-27.25K | (m) | (m) | (m) | 0.64× |
| 2014-03-31 | (m) | (m) | $-17.96K | (m) | (m) | $0.00 | (m) | $-27.25K | (m) | (m) | (m) | 0.66× |
| 2013-12-31 | (m) | (m) | $-22.91K | (m) | (m) | $0.00 | (m) | $-27.28K | (m) | (m) | (m) | 0.84× |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-27.23K | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-27.28K | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-26.58K | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | $-16.77K | (m) | (m) | $0.00 | (m) | $-25.59K | (m) | (m) | (m) | 0.66× |
| 2012-12-03 | (m) | (m) | $-16.77K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | (m) | $-13.65K | (m) | (m) | $0.00 | (m) | $-26.39K | (m) | (m) | (m) | 0.52× |
| 2012-06-30 | (m) | (m) | $-14.87K | (m) | (m) | $0.00 | (m) | $-25.49K | (m) | (m) | (m) | 0.58× |
| 2012-03-31 | (m) | (m) | $-17.18K | (m) | (m) | $0.00 | (m) | $-24.93K | (m) | (m) | (m) | 0.69× |
| 2011-12-31 | (m) | (m) | $-13.96K | (m) | (m) | $0.00 | (m) | $-24.05K | (m) | (m) | (m) | 0.58× |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | $-21.11K | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | $-13.66K | (m) | (m) | $0.00 | (m) | $-17.26K | (m) | (m) | (m) | 0.79× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Silexion Therapeutics Corp (SLXN) | $0.001B |